Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells

Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells

Abstract The integration of molecular targeted therapeutics with chimeric antigen receptor T (CAR-T) cell therapy represents a novel strategy to amplify the anti-tumor efficacy of immunotherapy. While CD19-targeted CAR-T cells and Janus kinase (JAK) inhibitors have independently shown efficacy again...

Full description

Saved in:
Bibliographic Details
Main Authors: Kohei Mitsuno, Masaya Suematsu, Yuki Naito, Azusa Mayumi, Hideki Yoshida, Shinya Osone, Toshihiko Imamura, Yozo Nakazawa, Shigeki Yagyu, Tomoko Iehara
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Cancer Immunology, Immunotherapy
Subjects:
CAR-T cell therapy
JAK2 inhibitor
Memory T cell fraction
Ph-like ALL
Online Access:https://doi.org/10.1007/s00262-024-03927-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03927-8

Similar Items